SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scinai Immunotherapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$13.2500 (−94.64%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Scinai Immunotherapeutics Ltd. grew revenue 99.2% to $1.31M over fiscal 2025. Free cash flow was -$6.06M.
Revenue
$1.31M
+99.2% vs. a year earlier
Operating income
-$7.54M
FY2025
Free cash flow
-$6.06M
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.31M
- Net income
- -$8.31M
- Free cash flow
- -$6.06M
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
$1.31M+99.2% YoY
Gross profit
-$2.65M
Operating income
-$7.54M
Net income
-$8.31M-273.2% YoY
EPS, diluted
–
Free cash flow
-$6.06M
Reported period